Having trouble accessing articles? Reset your cache.

Entresto’s heart failure miss may not signal the end, given FDA’s openness to new endpoints

Despite narrowly missing its primary endpoint in the PARAGON-HF trial to treat heart failure patients with preserved ejection fraction, Entresto’s performance on secondary endpoints suggests the drug could still have a path forward in the population, which currently lacks any approved therapies.

Novartis AG (NYSE:NVS; SIX:NOVN) reported Sunday

Read the full 479 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers